The Sites may contain information about parapharmaceuticals, drugs and possibly the texts or part of the texts of the Information Sheets (FI), the Summary of Product Characteristics (SPC) and the Summary of the European public assessment report (EPAR) of a drug.
FI, RCP and EPAR outline the conditions under which the medicine must be used and summarize the safety profile known to date. In particular:
- The Information Leaflet (FI) is a document intended for the patient / user. It contains all the information useful for a safer and more correct use of the drug.
- The Summary of Product Characteristics (RCP) is a document intended primarily for healthcare professionals (doctors, pharmacists, nurses) and is an "identity card" of the medicine, constantly updated over the years. It contains all the fundamental information concerning the efficacy and safety of the drug.
- The Summary of the European public assessment report (EPAR) outlines how the European Medicines Agency (EMA) evaluated the medicine and recommended its authorization in the EU and the conditions of use. It is not intended to provide practical advice on the use of drugs.
- For practical information on the use of drugs, patients must read the package leaflet and consult their doctor or pharmacist.
- For practical information on the use of parapharmaceuticals, users must read the information contained in the illustrative leaflet on the packaging and / or on the labels affixed to the packaging; it is also advisable to consult your doctor or pharmacist.
Information sheets (FI) and Summary of Product Characteristics (RCP) of a drug on the Site are a copy of the texts as spread by AIFA (Italian Drug Agency) on the website //farmaci.agenziafarmaco.gov. en.
The Summary of the European public assessment report (EPAR) on the Site is a copy of the texts as published by the EMA (European Medicinal Agency) on the website //www.ema.europa.eu/.
The data used and published are also taken from Farmadati Italia Data Banks. Farmadati Italia guarantees the maximum commitment to ensure that the database and updates are accurate, timely and up to date. The prescription and use of the products to which the data refer always take place under the sole and exclusive responsibility of the user. Farmadati Italia assumes no responsibility for the use of published data.
The term parapharmaceutical refers to cosmetic products, dietary foods and food supplements which - although not drugs - may have implications for the health of the user, as they contain concentrated sources of nutrients or other substances with a nutritional effect (eg vitamins, minerals, etc.) or physiological (eg plant extracts), alone or in combination.
Food supplements are not intended as a substitute for a varied and balanced diet and a healthy lifestyle. Although they may have a health value, food supplements may NOT have a therapeutic value; they can therefore contribute specifically to the well-being of the organism, but without goals of care. The indications relating to the use and properties of the parapharmaceuticals published on the Site must always and in any case be compared with the opinion of your doctor or pharmacist.
The information contained in FI, RCP and EPAR may be updated and modified several times during the period of validity of the medicinal product, therefore there may be differences between the information presented on the Sites and other information in the public domain.
The information present on the Sites once published may no longer be updated, therefore found dated, outdated and not updated.
To access the most up-to-date version of FI, RCP and EPAR, we recommend accessing the AIFA //farmaci.agenziafarmaco.gov.it website and the EMA //www.ema.europa.eu/ema/ .
Banzai Media, a Mondadori Group company, owner of this Site, DOES NOT guarantee the truthfulness and topicality of the information contained regarding drugs, parapharmaceuticals and in FI, RCP and EPAR and declines all responsibility for any errors or inaccuracies, omissions, or missed updates of the same.
Banzai Media assumes no liability for damages of any nature that may arise from access to the information contained in the contents concerning drugs, parapharmaceuticals and in FI, RCP and EPAR.
In this regard it is important to remember that:
- If you have any doubts or questions about the use of a medicine or a parapharmaceutical it is always necessary to contact your doctor, specialist or pharmacist.
- Any replies to comments or forums provided by professionals who manage / collaborate with the Site or in the Community cannot and should NEVER replace the direct medical-patient relationship that allows the practitioner to assess the patient's situation as a whole, through knowledge of clinical history, health status, allergies and other useful elements to define a diagnosis and appropriate treatment.
- Patients should never stop taking or varying the dosage (method of use) of a parapharmaceutical or a medicine that has been prescribed for them without first consulting their doctor and / or specialist.
- The information contained on the Site, in FI, RCP and EPAR and in any replies to comments or forums must never in any way replace the direct relationship between doctor and patient or between pharmacist and patient . For doubts or information of any kind, it is therefore advisable to consult your doctor and / or specialist.
- The formulation of diagnoses or prescription drugs is in no way possible through replies to comments or forums.
- The information about drugs, parapharmaceuticals and possibly the texts or part of the texts of the Information Sheets (FI), the Summary of Product Characteristics (SPC) and the European public assessment report (EPAR) of a drug do not in any way suggest or even indirectly favor the consumption of a specific product, in the choice of which it is always necessary to contact your doctor, specialist or pharmacist.
- The information disseminated on the Sites is aimed at adults and in good health.
